LUC7L2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Images
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Alternative names
CGI 59, CGI 74, FLJ10657, LC7L2_HUMAN, LUC7 like 2 (S. cerevisiae), LUC7B2, Putative RNA-binding protein Luc7-like 2, hLuc7B2
What's included?
Recommended products
LUC7L2 KO cell lysate available now. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
Key facts
- Cell type
- HEK-293T
- Species or organism
- Human
- Tissue
- Kidney
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.
- Concentration
Properties
- Gene name
- LUC7L2
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
- Zygosity
- Homozygous
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 2 US: 2
- Adherent/suspension
- Adherent
- Gender
- Female
Storage
- Shipped at conditions
- Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
- -20°C
- Appropriate long-term storage conditions
- -20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
LUC7L2 also known as LUC7-like 2 is an RNA-binding protein that plays a role in RNA splicing. It has a molecular mass of approximately 27 kDa. LUC7L2 is expressed in a variety of tissues with a higher expression in the brain and reproductive tissues. It has a specific domain structure that enables it to bind to RNA molecules influencing pre-mRNA processing. The protein is also known to interact with other splicing factors contributing to its function in the cellular nucleus.
- Biological function summary
LUC7L2 is an important factor in the regulation of gene expression. It is part of the spliceosome complex which is responsible for the precisely regulated removal of introns from pre-mRNA. This activity impacts the generation of mature mRNA and consequently protein synthesis. LUC7L2 interacts with other components of the spliceosome like the U1 snRNP which ensures accurate and efficient splicing. Through these interactions LUC7L2 helps maintain the fidelity of the splicing process affecting cell function and health.
- Pathways
LUC7L2 participates in the mRNA splicing pathway also known as the spliceosome cycle. This protein is involved in both the recognition of splice sites and the catalytic steps of splicing. LUC7L2's activity influences alternative splicing patterns which diversifies the proteome. It interacts with other proteins like the SR proteins which modulate splicing decisions. Its role in the spliceosome cycle highlights its contribution to gene expression regulation.
- Associated diseases and disorders
LUC7L2 has been implicated in neurological disorders and certain cancers. Alterations in LUC7L2 expression or function can lead to aberrant splicing events that disrupt normal cellular activity. In some cancers LUC7L2's interaction with proteins like SF3B1 another spliceosomal component becomes dysregulated contributing to tumorigenesis. Understanding LUC7L2's function and interactions may help develop therapeutic strategies for conditions linked to splicing dysregulation.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
1 product image
Sanger Sequencing - Human LUC7L2 knockout HEK-293T cell lysate (ab258036)
Homozygous: 1 bp insertion in exon 2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com